Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 119.97

-2.9%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	9/22/2005 7:27:46 AM
	of 276

Illumina and GlaxoSmithKline Sign Agreement for Large-Scale Genotyping Studies Thursday September 22, 6:00 am ET SAN DIEGO--(BUSINESS WIRE)--Sept. 22, 2005--(NASDAQ: ILMN - News) announced today that it has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Illumina will use Sentrix® Arrays in conjunction with the Company's GoldenGate® and Infinium(TM) assays to conduct genetic studies for thousands of samples provided by GSK. The blanket agreement enables multiple projects to be conducted over period of time. ADVERTISEMENT Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies. The Company is providing no further detail. About Illumina Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next